Clopidogrel
Product Images NDC 68645-430

This is a description of Clopidogrel tablets, a prescription drug used for treating heart attacks, strokes, and acute coronary syndromes. Each tablet contains 75mg of clopidogrel bisulfate, USP equivalent to 75 mg of clopidogrel base. The tablets are packaged in a bottle containing 30 tablets with tamper-evident seals. The drug information sheet accompanying the tablets contains thorough drug information to be read before use. It is a requirement to tighten the cap on the bottle after each use, and the tablets are to be stored at room temperature and protected from moisture, freezing, and excessive heat. This product is child-resistant and should be kept out of reach of children. The product is distributed by Wal-Mart and manufactured by TEVA PHARMACEUTICALS USA. The packaging is done by Legacy Pharmaceutical Packaging LLC.*

This is a data table displaying the cumulative event rate of cardiovascular death, myocardial infarction, and stroke for patients taking either placebo/aspirin or clopidogrel/aspirin over a period of months. The table indicates that clopidogrel plus aspirin has a significantly lower event rate compared to the placebo plus aspirin group (p = 0.000008). Other standard therapies were also used in both groups.*

The given text seems to be a report on a clinical trial evaluating the efficacy of a medication called Clopidogrel. The text also indicates that there was a group that received a placebo as part of the study. The report provides information on the number of deaths, both before and after the first discharge, in each of the two groups, along with the proportion of deaths in each group. Additionally, the text mentions a 7% reduction in risk associated with the use of Clopidogrel, which was found to be statistically significant (p = 0.03). The number of days since randomization was also recorded in the study, up to a maximum of 28 days.*

This is a statistical report on a clinical trial of placebo versus clopidogrel. The report compares the percentage of patients with events (10.1% for placebo versus 9.2% for clopidogrel) and the proportional risk reduction (97.9%) for death, reinfarction, or stroke before discharge. The report also includes a graph depicting days since randomization up to 28 days.*

This appears to be a table containing various medical data, including baseline events, odds ratios, and heterogeneity related to treatment with Clopidogrel versus a placebo or trend fest. The data includes information about sex, age, heart rate, fibrinolytic agent given, and prognostic index. There is also information about Metoprolol allocation and proportional reduction with a global heterogeneity test.*

The text seems to be a table showing the odds ratio and confidence intervals for events in a study comparing Clopidogrel to Placebo. The table compares these results based on the categorization of Killip class, previous myocardial infarction, and infarct location. There appears to be some heterogeneity in the results. The global heterogeneity test produces a p-value of 0.03. The odds ratios and 95% or 99% confidence intervals for the different categories are also shown.*

This is a chart that shows the cumulative event rate for fatal or non-fatal vascular events between two drugs: Aspirin and Clopidogrel. The chart shows the percentage rate for each drug over a period of several months of follow-up. The chart also shows that there is a statistically significant difference between the two drugs with a p-value of 0.045.*